Evidence map›Paper›PMID 38333456›Full record

ReviewCureus2024

Stevens-Johnson Syndrome From Combined Allopurinol and Angiotensin-Converting Enzyme Inhibitors: A Narrative Review.

Isabella M Fabian, Kirsten Maddox, Cameron Robicheaux, Rahib K Islam, Ahmed Anwar, Bradley Dorius, Christopher L Robinson, Adam M Kaye, Giustino Varrassi, Shahab Ahmadzadeh and 2 more

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Isabella M FabianSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Kirsten MaddoxSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Cameron RobicheauxSchool of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA.
Rahib K IslamSchool of Medicine, Louisiana State University Health Sciences Center (LSUHSC) New Orleans, New Orleans, USA.
Ahmed AnwarDepartment of Psychology, Quinnipiac University, Hamden, USA.
Bradley DoriusDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Christopher L RobinsonDepartment of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences University of the Pacific, Stockton, USA.
Giustino VarrassiDepartment of Pain Medicine, Paolo Procacci Foundation, Rome, ITA.
Shahab AhmadzadehDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Sahar ShekoohiDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA.
University of the Pacific · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stevens-Johnson syndrome (SJS) is a severe and potentially debilitating skin reaction frequently related to medication use. Allopurinol and angiotensin-converting enzyme (ACE) inhibitors are commonly prescribed medications for prevalent health conditions worldwide, and their interaction associated with SJS warrants further investigation. A comprehensive literature search was performed to investigate cases as studies related to SJS occurring in patients with concomitant use of allopurinol and ACE inhibitors. We identified case reports and studies detailing hypersensitivity reactions, including SJS, attributed to a combination of allopurinol and ACE inhibitors. Despite the drug-drug interactions or lack thereof seen in patient populations, there is no definitive evidence of a pharmacokinetic interaction between allopurinol and ACE inhibitors. We were only able to find one case report specifically detailing SJS in a patient on combined ACE inhibitors and allopurinol. While the exact mechanism of the interaction is unclear, those reported cases of severe hypersensitivity reactions suggest a previous history of impaired renal function as a predisposing factor in the development of SJS. The potential risk of SJS with coadministration of ACE inhibitors and allopurinol is a drug-drug interaction that physicians should be aware of. This topic requires additional attention to determine if this drug combination should be avoided entirely in certain patients.

Indexed as

ace inhibitorsallopurinolangiotensin converting enzyme inhibitorsdrug reactionstevens-johnson syndrome

Identifiers

PMID38333456
PMCPMC10850002
OpenAlexW4390684758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.